
Perspectives of Healthcare Providers and Patients with Relapsed/Refractory Multiple Myeloma on Treatment Priorities and ...
Introduction Multiple myeloma (MM) is the second most common hematologic malignancy in high-income countries and is associated with significant morbidity and mortality.1,2 The global treatment landscape for relapsed/refractory MM (RRMM) has become …